1. Home
  2. KNRX vs LIXT Comparison

KNRX vs LIXT Comparison

Compare KNRX & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNRX

KNOREX LTD. Class A Ordinary Shares

N/A

Current Price

$0.86

Market Cap

27.4M

Sector

Technology

ML Signal

N/A

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$2.90

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNRX
LIXT
Founded
2009
2005
Country
Singapore
United States
Employees
N/A
4
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
25.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KNRX
LIXT
Price
$0.86
$2.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.8M
48.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$0.64
52 Week High
$3.45
$6.09

Technical Indicators

Market Signals
Indicator
KNRX
LIXT
Relative Strength Index (RSI) 43.10 38.37
Support Level $0.77 $2.45
Resistance Level $2.05 $4.45
Average True Range (ATR) 0.37 0.22
MACD -0.02 0.00
Stochastic Oscillator 5.11 11.21

Price Performance

Historical Comparison
KNRX
LIXT

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: